ACM
VRDN icon

Atika Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Atika Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-167,000
Closed -$3.8M – 114
2024
Q3 		$3.8M Buy
+167,000
New +$2.73M 0.39% 68
2024
Q1 		– Sell
-39,000
Closed -$849K – 114
2023
Q4 		$849K Buy
+39,000
New +$616K 0.11% 73

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Atika Capital Management's VRDN Position: Q4 2024 in Review

Atika Capital Management sold out of Viridian Therapeutics (VRDN) in Q4 2024, closing a stake of 167,000 shares — an estimated $3.8M sold.

Atika Capital Management first reported a position in VRDN in Q4 2023 and held it in 2 quarters. The position peaked at $3.8M in Q3 2024. 178 funds tracked by Wall St. Rank hold VRDN as of Q4 2024.

  • Atika Capital Management reported no remaining Viridian Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Atika Capital Management sold 167,000 Viridian Therapeutics shares in Q4 2024, an estimated $3.8M.
  • Atika Capital Management first reported a position in Viridian Therapeutics in Q4 2023 and held it in 2 quarters.
  • Atika Capital Management's Viridian Therapeutics position peaked at $3.8M in Q3 2024.
  • 178 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2024.

Based on Atika Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.